<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152825</url>
  </required_header>
  <id_info>
    <org_study_id>CARISMA_CTO</org_study_id>
    <nct_id>NCT03152825</nct_id>
  </id_info>
  <brief_title>Stress CMR in Patients With Coronary Chronic Total Occlusions</brief_title>
  <acronym>CARISMA_CTO</acronym>
  <official_title>Stress Perfusion Cardiac Magnetic Resonance for Ischaemia and Viability Detection in Patients With Coronary Chronic Total Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total chronic occlusion (CTO) is defined as a coronary obstruction with TIMI 0 flow lasting
      at least 3 months.The prevalence of CTO in patients with coronary disease is about 10-40%.
      Coronary collateralizations may supply sufficient perfusion to retain tissue viability, but
      do not protect from myocardial ischaemia. In fact, percutaneous revascularization (PCI) of
      CTO lesions leads to improved symptoms, functional class, quality of life, higher left
      ventricular ejection fraction and improved survival in several observational studies.
      However, due to the higher rate of procedural complications and lower success rate of PCI
      than in other settings, it is attempted in only 10% of all CTO lesions. Myocardial
      viability/ischaemia assessment should be performed before PCI to avoid potential PCI-related
      complications and identify patients who might benefit most from myocardial revascularization,
      individualizing the risk-to-benefit ratio. In this regard, patients with stable coronary
      artery disease who have moderate-to-severe ischaemia are at higher risk of event rates (death
      or MI of ~5%/year) and plausibly represent the best target for PCI.

      Cardiac MRI (CMR) provide a reliable assessment of both myocardial ischaemia and viability.
      Using late gadolinium enhancement (LGE) sequences, myocardial segments with LGE &gt;75% of
      transmurality do not show any improvement in contractility even after revascularization,
      representing a subset of patients in which CTO PCI may be futile. Viability assessment by CMR
      may be also performed with low dose dobutamine infusion; in patients with CTO and akinetic
      segments, contractility improvement at low dose dobutamine may predict functional recovery in
      the follow-up. Myocardial ischaemia may be assessed by CMR with high accuracy, identifying
      perfusion defects during pharmacological-induced hyperemia and/or regional wall motion
      abnormalities during inotrope infusion.

      This study is designed to verify the hypothesis that myocardial ischaemia and viability
      assessed by CMR could identify patients who are more likely to benefit from PCI in terms of
      improvement in left ventricular remodeling, functional recovery and clinical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Left ventricular mechanical improvement after PCI</measure>
    <time_frame>12 +/- 3 months</time_frame>
    <description>At least ONE of the following:
Delta ejection fraction ≥ 5%
Segmental function improvement ≥1 grade
Delta end-diastolic volume ≥ 10%
Delta end-systolic volume ≥ 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stress ischaemia improvement after PCI</measure>
    <time_frame>12 +/- 3 months</time_frame>
    <description>At least ONE of the following stress CMR (adenosine or dobutamine) findings:
_&lt;1.5 segments perfusion defect
_≥1 grade improvement in segmental wall motion abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>12+/-3 months</time_frame>
    <description>Delta SAQ score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>12+/- 3 months</time_frame>
    <description>all-cause death, death for cardiovascular cause, life-threatening arrythmia, hospitalization for heart failure, myocardial infarction, target vessel revascularization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CMR to identify re-occlusion of CTO</measure>
    <time_frame>12 +/- 3 months</time_frame>
    <description>Correlate angiographic CTO re-occlusion and/or critical re-stenosis with at least ONE of the following stress CMR parameters:
Segmental perfusion defect ≥1.5
New segmental contractility impairment
Delta ejection fraction, end-diastolic,end-systolic volume</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Chronic Total Occlusions</condition>
  <arm_group>
    <arm_group_label>Viable myocardium Group</arm_group_label>
    <description>At least ONE of the following:
Late gadolinium enhancement &lt;75%.
Improvement in segmental function ≥1 grade during low dose dobutamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-viable myocardium group</arm_group_label>
    <description>At least ONE of the following:
Late gadolinium enhancement ≥75%.
No improvement in segmental function during low dose dobutamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inducible ischaemia group</arm_group_label>
    <description>At least ONE of the following:
perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine
new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-inducible ischaemia group</arm_group_label>
    <description>None of conditions qualifying for the &quot;Inducible ischemia group&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>percutaneous coronary intervention attempt</description>
    <arm_group_label>Viable myocardium Group</arm_group_label>
    <arm_group_label>Non-viable myocardium group</arm_group_label>
    <arm_group_label>Inducible ischaemia group</arm_group_label>
    <arm_group_label>Non-inducible ischaemia group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with angiographic evidence of CTO with planned PCI.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographic diagnosis of Coronary Chronic Total Occlusion (TIMI 0 lasting more than 3
             months, if known)

          -  baseline stress CMR

          -  signed informed consent

        Exclusion Criteria:

          -  CMR contraindications

          -  severe CKD

          -  contraindications to adenosine or dobutamine

          -  unable/unwilling to sign informed consent

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Lombardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Lombardi, MD</last_name>
    <phone>+390252774376</phone>
    <email>massimo.lombardi@grupposandonato.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Pica, MD</last_name>
    <phone>+390252774376</phone>
    <email>silvia.pica@grupposandonato.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Pica, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, Moussa I, Teirstein PS, Dangas G, Baim DS, Selmon M, Strauss BH, Tamai H, Suzuki T, Mitsudo K, Katoh O, Cox DA, Hoye A, Mintz GS, Grube E, Cannon LA, Reifart NJ, Reisman M, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005 Oct 11;112(15):2364-72.</citation>
    <PMID>16216980</PMID>
  </reference>
  <reference>
    <citation>Shah PB. Management of coronary chronic total occlusion. Circulation. 2011 Apr 26;123(16):1780-4. doi: 10.1161/CIRCULATIONAHA.110.972802. Review.</citation>
    <PMID>21518991</PMID>
  </reference>
  <reference>
    <citation>Baim DS, Kwong RY. Is magnetic resonance image guidance the key to opening chronic total occlusions? Circulation. 2006 Feb 28;113(8):1053-5.</citation>
    <PMID>16505189</PMID>
  </reference>
  <reference>
    <citation>Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J. 1993 Sep;126(3 Pt 1):561-4.</citation>
    <PMID>8362709</PMID>
  </reference>
  <reference>
    <citation>Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005 May 1;95(9):1088-91.</citation>
    <PMID>15842978</PMID>
  </reference>
  <reference>
    <citation>Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):284-90. doi: 10.1161/CIRCOUTCOMES.108.825760. Epub 2010 Apr 13.</citation>
    <PMID>20388873</PMID>
  </reference>
  <reference>
    <citation>Cheng AS, Selvanayagam JB, Jerosch-Herold M, van Gaal WJ, Karamitsos TD, Neubauer S, Banning AP. Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility: insights from quantitative cardiovascular magnetic resonance imaging. JACC Cardiovasc Interv. 2008 Feb;1(1):44-53. doi: 10.1016/j.jcin.2007.11.003.</citation>
    <PMID>19393143</PMID>
  </reference>
  <reference>
    <citation>Pujadas S, Martin V, Rosselló X, Carreras F, Barros A, Leta R, Alomar X, Cinca J, Sabate M, Pons-Llado G. Improvement of myocardial function and perfusion after successful percutaneous revascularization in patients with chronic total coronary occlusion. Int J Cardiol. 2013 Oct 30;169(2):147-52. doi: 10.1016/j.ijcard.2013.08.017. Epub 2013 Aug 15.</citation>
    <PMID>24120215</PMID>
  </reference>
  <reference>
    <citation>Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, Rangan BV, Abdullah S, Grodin J, Kumbhani DJ, Vo M, Luna M, Alaswad K, Karmpaliotis D, Rinfret S, Garcia S, Banerjee S, Brilakis ES. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. Am J Cardiol. 2015 May 15;115(10):1367-75. doi: 10.1016/j.amjcard.2015.02.038. Epub 2015 Feb 18. Review.</citation>
    <PMID>25784515</PMID>
  </reference>
  <reference>
    <citation>Hoebers LP, Claessen BE, Elias J, Dangas GD, Mehran R, Henriques JP. Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. Int J Cardiol. 2015;187:90-6. doi: 10.1016/j.ijcard.2015.03.164. Epub 2015 Mar 17. Review.</citation>
    <PMID>25828320</PMID>
  </reference>
  <reference>
    <citation>Jang WJ, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Kim WS, Lee YT, Gwon HC. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. JACC Cardiovasc Interv. 2015 Feb;8(2):271-279. doi: 10.1016/j.jcin.2014.10.010.</citation>
    <PMID>25700750</PMID>
  </reference>
  <reference>
    <citation>Valenti R, Migliorini A, Signorini U, Vergara R, Parodi G, Carrabba N, Cerisano G, Antoniucci D. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur Heart J. 2008 Oct;29(19):2336-42. doi: 10.1093/eurheartj/ehn357. Epub 2008 Aug 5.</citation>
    <PMID>18682446</PMID>
  </reference>
  <reference>
    <citation>Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445-53.</citation>
    <PMID>11078769</PMID>
  </reference>
  <reference>
    <citation>Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, Neubauer S. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004 Sep 21;110(12):1535-41. Epub 2004 Sep 7.</citation>
    <PMID>15353496</PMID>
  </reference>
  <reference>
    <citation>Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003 Feb 1;361(9355):374-9.</citation>
    <PMID>12573373</PMID>
  </reference>
  <reference>
    <citation>Baks T, van Geuns RJ, Duncker DJ, Cademartiri F, Mollet NR, Krestin GP, Serruys PW, de Feyter PJ. Prediction of left ventricular function after drug-eluting stent implantation for chronic total coronary occlusions. J Am Coll Cardiol. 2006 Feb 21;47(4):721-5. Epub 2006 Jan 26.</citation>
    <PMID>16487835</PMID>
  </reference>
  <reference>
    <citation>Kirschbaum SW, Baks T, van den Ent M, Sianos G, Krestin GP, Serruys PW, de Feyter PJ, van Geuns RJ. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol. 2008 Jan 15;101(2):179-85. doi: 10.1016/j.amjcard.2007.07.060. Epub 2007 Dec 3.</citation>
    <PMID>18178403</PMID>
  </reference>
  <reference>
    <citation>Wellnhofer E, Olariu A, Klein C, Gräfe M, Wahl A, Fleck E, Nagel E. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation. 2004 May 11;109(18):2172-4. Epub 2004 Apr 26.</citation>
    <PMID>15117834</PMID>
  </reference>
  <reference>
    <citation>Bellenger NG, Yousef Z, Rajappan K, Marber MS, Pennell DJ. Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery. Heart. 2005 Apr;91(4):478-83.</citation>
    <PMID>15772205</PMID>
  </reference>
  <reference>
    <citation>Fiocchi F, Sgura F, Di Girolamo A, Ligabue G, Ferraresi S, Rossi R, D'Amico R, Modena MG, Torricelli P. Chronic total coronary occlusion in patients with intermediate viability: value of low-dose dobutamine and contrast-enhanced 3-T MRI in predicting functional recovery in patients undergoing percutaneous revascularisation with drug-eluting stent. Radiol Med. 2009 Aug;114(5):692-704. doi: 10.1007/s11547-009-0426-2. Epub 2009 Jun 23. English, Italian.</citation>
    <PMID>19551341</PMID>
  </reference>
  <reference>
    <citation>Schwitter J, Arai AE. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. Eur Heart J. 2011 Apr;32(7):799-809. doi: 10.1093/eurheartj/ehq481. Epub 2011 Mar 11. Review.</citation>
    <PMID>21398645</PMID>
  </reference>
  <reference>
    <citation>Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R, Fleck E, Paetsch I. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007 Apr 3;115(13):1769-76. Epub 2007 Mar 12.</citation>
    <PMID>17353441</PMID>
  </reference>
  <reference>
    <citation>Gebker R, Jahnke C, Manka R, Hamdan A, Schnackenburg B, Fleck E, Paetsch I. Additional value of myocardial perfusion imaging during dobutamine stress magnetic resonance for the assessment of coronary artery disease. Circ Cardiovasc Imaging. 2008 Sep;1(2):122-30. doi: 10.1161/CIRCIMAGING.108.779108. Epub 2008 Jul 30.</citation>
    <PMID>19808529</PMID>
  </reference>
  <reference>
    <citation>Gebker R, Frick M, Jahnke C, Berger A, Schneeweis C, Manka R, Kelle S, Klein C, Schnackenburg B, Fleck E, Paetsch I. Value of additional myocardial perfusion imaging during dobutamine stress magnetic resonance for the assessment of intermediate coronary artery disease. Int J Cardiovasc Imaging. 2012 Jan;28(1):89-97. doi: 10.1007/s10554-010-9764-3. Epub 2010 Dec 14.</citation>
    <PMID>21153708</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Donato</investigator_affiliation>
    <investigator_full_name>Massimo Lombardi</investigator_full_name>
    <investigator_title>Director of Multimodality Cardiac Imaging Unit</investigator_title>
  </responsible_party>
  <keyword>myocardial ischaemia</keyword>
  <keyword>myocardial viability</keyword>
  <keyword>coronary chronic total occlusions</keyword>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>stress CMR</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

